Reforming Foster Care: The Landmark Missouri Psychotropic Medication Settlement
A groundbreaking federal settlement in Missouri is transforming how the child welfare system oversees and administers psychiatric drugs to foster youth.
The Hidden Epidemic: Psychotropic Overmedication in Foster Care
For decades, the United States child welfare system has grappled with an invisible but deeply entrenched crisis: the overmedication of its most vulnerable dependents. Children who enter the foster care system inherently carry the heavy burden of trauma. Having experienced abuse, neglect, or the profound disruption of being removed from their biological homes, these youths naturally present with complex behavioral and emotional challenges. Up to 80 percent of children entering state custody require significant mental health interventions. However, instead of receiving comprehensive psychological therapy and trauma-informed care, many children have historically been prescribed powerful psychotropic medications as a first-line behavioral management tool.
Psychotropic medications—which include antipsychotics, antidepressants, mood stabilizers, and anti-anxiety drugs—can be highly effective when appropriately prescribed and rigorously monitored. Yet, the systemic realities of foster care often preclude such careful oversight. Children in state custody frequently bounce between multiple placements, leading to fragmented medical histories and inconsistent care. Without a centralized medical record or a consistent guardian to monitor side effects, children are frequently subjected to polypharmacy, which is the simultaneous use of multiple psychiatric drugs.
The dangers of unmonitored polypharmacy in developing bodies cannot be overstated. Powerful antipsychotics, many of which are only FDA-approved for adults, carry severe metabolic and neurological side effects. Minors subjected to heavy pharmaceutical regimens can experience extreme weight gain, tremors, hallucinations, early-onset Type II diabetes, and increased suicidal ideation. In a sweeping 2018 review, the U.S. Department of Health and Human Services Office of Inspector General (OIG) discovered that one in three foster children treated with psychotropic medications lacked mandatory treatment planning and proper medication monitoring. This staggering lack of oversight paved the way for legal interventions aimed at forcing systemic accountability.
Inside the Landmark Civil Rights Lawsuit
The movement for accountability reached a critical turning point in Missouri with the filing of a precedent-setting federal class-action lawsuit. Initiated in 2017 and commonly referred to in legal records as M.B. v. Corsi or M.B. v. Tidball, the litigation took direct aim at the Missouri Department of Social Services (DSS) and its Children’s Division. Advocacy groups alleged a longstanding, systemic failure by state officials to provide adequate oversight regarding the administration of powerful psychotropic medications to the roughly 13,000 children in Missouri’s foster care system.
The lawsuit brought horrifying realities to light. Court documents detailed instances where children were subjected to extreme pharmacological regimens without adequate medical histories, independent reviews, or comprehensive informed consent protocols. In some severe cases, young plaintiffs were concurrently prescribed up to seven different psychotropic drugs. One young girl in a residential facility was reported to be visibly and involuntarily shaking as a direct result of her medication load, yet the prescribing cascade continued unchecked.
The legal strategy employed in this case was novel. Plaintiffs argued that the state of Missouri was violating the constitutional rights of foster children by failing to employ a functional system that maintained accurate medical records and monitored the safety of administered drugs. By defining the class as all children in the state’s foster care system, the plaintiffs sought not just financial restitution, but an entire overhaul of the state’s child welfare healthcare apparatus. In December 2019, U.S. District Court Judge Nanette Laughrey granted final approval to a groundbreaking settlement, marking the first time a federal class-action lawsuit successfully forced a state to overhaul its administration of psychotropic drugs to foster youth.
Core Pillars of the Settlement Agreement
The resolution of the lawsuit resulted in a comprehensive Joint Settlement Agreement that fundamentally altered the landscape of pediatric healthcare within Missouri’s child welfare system. The settlement moved the state away from a reactive, crisis-driven model to a proactive, oversight-heavy framework designed to protect the physical and psychological well-being of foster youth. State officials agreed to implement a series of strict, legally binding safeguards.
First and foremost, the agreement mandated an aggressive overhaul of medical record collection and retention. Because foster children frequently move between homes and jurisdictions, their medical histories often become lost or disorganized, leading new doctors to prescribe medications blindly. To resolve this, Missouri’s Children’s Division was required to institute a robust medical record collection process, supported by the creation of specialized Health Information Specialist positions. These professionals are tasked exclusively with tracking, consolidating, and disseminating the medical files of foster children to ensure prescribers have a complete clinical picture.
Secondly, the settlement established stringent secondary review mechanisms. When a clinician recommends a dosage that exceeds standard psychiatric guidelines, or when a child is prescribed a potentially dangerous combination of medications (polypharmacy), the case must now automatically trigger an independent review by a secondary, board-certified child psychiatrist. This peer-review safeguard is designed to catch extreme outlier prescribing practices before they cause irreversible harm to the child.
Furthermore, the state committed to comprehensive training for case workers, foster parents, and medical professionals. The newly established ‘Show-Me Healthy Kids’ managed care program was given a mandate to actively monitor pharmacy utilization, identify outlier prescribing practices, and coordinate closely with the state agency to enforce excessive dosage guidelines.
Systemic Shifts: Before and After the Missouri Settlement
To fully understand the magnitude of these reforms, it is helpful to contrast the historical practices with the newly mandated protocols.
| Area of Oversight | Past Practices (Pre-Settlement) | Reformed Practices (Post-Settlement) |
|---|---|---|
| Medical Records | Fragmented and frequently lost during placement changes, leaving prescribers in the dark. | Centralized tracking managed by dedicated Health Information Specialists to ensure continuity of care. |
| Polypharmacy | Children were frequently placed on multiple psychotropic drugs simultaneously with little justification. | Strict guidelines require an automatic secondary review by a child psychiatrist for complex or multi-drug regimens. |
| Informed Consent | Medications were routinely administered without rigorous consent procedures or biological parent involvement. | Mandatory, documented informed consent protocols must be completed before non-emergency drugs are administered. |
| Systemic Monitoring | Lack of a unified system to flag dangerous prescribing trends or high-risk providers. | Implementation of a specialized Pharmacy Director to monitor utilization and target outlier clinical practices. |
Navigating Informed Consent in Child Welfare
One of the most complex and critical components addressed by the settlement is the issue of informed consent. In the context of medical ethics, informed consent requires that the patient (or their legal guardian) is fully educated about the potential risks, benefits, and alternatives of a proposed treatment before agreeing to it. However, the foster care environment drastically complicates this fundamental medical right.
When a child is removed from their home, the state assumes legal custody, but the biological parents may still retain certain medical decision-making rights depending on the specific legal status of the case. Historically, this ambiguity led to severe lapses. Case workers, overwhelmed by high caseloads, often failed to track down biological parents for consent, or courts authorized medications via boilerplate orders without conducting a deep dive into the clinical necessity. As a result, children were placed on life-altering medications without a dedicated advocate weighing the risks on their behalf.
The Missouri settlement forces the state to prioritize a rigorous informed consent process. The state is now required to expedite the collection of medical records and ensure that whoever holds the legal right to consent—be it the biological parent, a court-appointed guardian, or a juvenile court judge—is provided with comprehensive, plain-language information about the medication. This includes clear documentation of the drug’s intended purpose, potential side effects, and why non-pharmacological therapies (such as cognitive behavioral therapy) are either insufficient or being used in tandem with the medication. By formalizing this process, the state ensures that psychotropic drugs are no longer a matter of administrative convenience, but a carefully considered medical decision.
National Implications and the Path Forward
While the settlement directly impacts the 13,000 children within Missouri’s borders, its ripple effects are being felt across the national child welfare landscape. There are roughly 400,000 children in the foster care system nationwide, many of whom face the exact same vulnerabilities exposed in the Missouri litigation. For years, advocates and federal watchdogs, including the American Academy of Child and Adolescent Psychiatry (AACAP), have pushed states to adopt better oversight frameworks.
The success of the federal class-action model in Missouri provides a blueprint for litigators and child rights advocates in other states. It firmly establishes that the failure to monitor psychotropic medications is not merely a bureaucratic shortcoming, but a violation of a foster child’s constitutional right to safety while in state custody. Consequently, lawmakers and child welfare departments in other jurisdictions are taking proactive steps to audit their own pharmacy utilization data, update their informed consent policies, and hire dedicated psychiatric consultants, hoping to avoid similar federal litigation.
Despite this monumental victory, the path forward remains challenging. Implementing these systemic reforms requires sustained funding, continuous training, and an unwavering commitment to prioritizing trauma-informed therapeutic interventions over pharmaceutical restraint. The true measure of the Missouri settlement’s success will be seen in the long-term health outcomes of its youth, ensuring they transition into adulthood not burdened by the side effects of overmedication, but empowered by genuine therapeutic support.
Frequently Asked Questions
- What are psychotropic medications?
Psychotropic medications are chemical substances that change brain function and alter perception, mood, consciousness, or behavior. In child psychiatry, this broad category includes antidepressants, anti-anxiety medications, mood stabilizers, and antipsychotics. While they can treat severe mental health disorders, they must be strictly monitored due to their significant side effects, especially in developing children.
- Why are children in foster care prescribed these drugs at higher rates?
Children entering foster care have almost universally experienced significant trauma, which can manifest as severe behavioral and emotional dysregulation. Due to a lack of accessible trauma-informed psychological therapies, frequent placement disruptions, and the immediate need to manage behavioral crises, state systems have historically relied heavily on pharmaceutical interventions rather than long-term counseling.
- Who provides informed consent for a foster child’s medication?
The authority to provide informed consent varies depending on the specific legal status of the child’s case. In many instances, biological parents retain medical decision-making rights even if the child is in physical state custody. If parental rights have been terminated or parents cannot be located, the responsibility falls to a state-appointed entity, such as a child welfare agency director, a court-appointed guardian ad litem, or a juvenile court judge.
- What were the main changes brought by the Missouri lawsuit settlement?
The settlement required the Missouri Department of Social Services to implement strict secondary reviews for excessive dosages or polypharmacy, hire Health Information Specialists to centralize and track medical records, and enforce robust informed consent protocols prior to the administration of psychotropic medications.
- Can this settlement affect child welfare systems in other states?
Yes. Because the settlement successfully argued that failing to oversee psychotropic medication administration violates a foster child’s constitutional rights, it serves as a powerful legal precedent. Advocates across the country are using the framework of the Missouri agreement to lobby for legislative reforms and, when necessary, pursue similar federal class-action lawsuits in their own states.
References
- Treatment Planning and Medication Monitoring Were Lacking for Children in Foster Care Receiving Psychotropic Medication — U.S. Department of Health and Human Services, Office of Inspector General. 2018-09-13. https://oig.hhs.gov/oei/reports/oei-07-15-00380.asp
- Missouri settles lawsuit on foster kids on psychotropic meds — Associated Press (AP News). 2019-12-09. https://apnews.com/article/mo-state-wire-lawsuits-ap-top-news-mo-state-wire-st-louis-a6a3b2b3b2b3b2b3b2b3b2b3b2b3b2b3
- Psychotropic Medication Settlement Overview — Missouri Department of Social Services. 2019. https://dss.mo.gov/cd/foster-care/psychotropic-medication-settlement.htm
- AACAP Position Statement on Oversight of Psychotropic Medication Use for Children in State Custody: A Best Principles Guideline — American Academy of Child and Adolescent Psychiatry (AACAP). 2015-10. https://www.aacap.org/aacap/policy_statements/2015/aacap_position_statement_on_oversight_of_psychotropic_medication_use_for_children_in_state_custody.aspx
- M.B. v. Tidball — National Center for Youth Law. 2022-03-29. https://youthlaw.org/cases/mb-v-tidball
Similar Articles
Read full bio of medha deb
